INmune Bio Inc (NAS:INMB)

Q2 2025 INmune Bio Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $2.79 (+1.09%)

Transcript 8-K10-Q

Key Points

Positve

INmune Bio Inc (INMB) reported promising results from their phase 2 trial of XPro, particularly in Alzheimer's patients with high inflammation, indicating a potential first-in-class treatment.
The company is exploring strategic partnerships to advance XPro, with preliminary conversations already underway.
Cordstrom has shown great promise in treating recessive dystrophic epidermolysis bullosa (RDEB) and may qualify for a priority review voucher if approved in the US.
The company has a robust pipeline with clear paths to potential value creation, including the potential extension of the rare pediatric disease priority review voucher program.
INmune Bio Inc (INMB) has sufficient cash reserves to fund operations into Q3 of 2026, providing financial stability for ongoing projects.

Negative

The phase 2 trial of XPro did not meet its primary endpoint in the overall population, raising concerns about its efficacy across all Alzheimer's patients.
The company has decided to halt immediate plans to further develop XPro in Alzheimer's disease due to the high cost of a phase 3 program.
There is no assurance of a strategic partnership for XPro, which could delay its advancement to phase 3 trials.
Net loss attributable to common stockholders increased significantly to approximately $24.5 million compared to $9.7 million in the previous year.
The company faces challenges in advancing its programs with limited resources, necessitating strategic partnerships or alternative funding sources.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INMB.OQ - INmune Bio Inc
Q2 2025 INmune Bio Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Immune bio Second quarter 2025 earnings call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing 1 on your touchtone phone. You may withdraw yourself from the queue by pressing 2.

As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.

At this time, it is my pleasure to introduce Mr. Daniel Carlson, head of investor relations at Immune Bio. Daniel.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.